Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 4332

Drug Profile

CB 4332

Alternative Names: CB-4332; Enhanced CFI; Enhanced complement Factor I; SQ CB 4332

Latest Information Update: 01 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catalyst Biosciences
  • Developer Gyre Therapeutics
  • Class Anti-inflammatories; Complement system proteins; Recombinant proteins; Serine endopeptidases; Urologics
  • Mechanism of Action Complement factor I replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glomerulonephritis; Haemolytic uraemic syndrome; Immunodeficiency disorders; Membranoproliferative glomerulonephritis

Most Recent Events

  • 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
  • 25 Jan 2022 CB 4332 receives rare pediatric disease designation (RPDD) for Complement Factor I (CFI) deficiency (CFID) in USA
  • 09 Sep 2021 Catalyst Biosciences plans a global phase I/II trial for Immunodeficiency disorders (CFI deficiency) in mid-2022 (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top